Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study

BACKGROUND: Infants born at 33–35 completed weeks’ gestational age (wGA) aged <6 months at the start of or born during respiratory syncytial virus (RSV) season and classified as moderate/high risk of severe RSV disease were included in a palivizumab RSV prophylaxis program in the province of Queb...

Descripción completa

Detalles Bibliográficos
Autores principales: Papenburg, Jesse, Defoy, Isabelle, Massé, Edith, Caouette, Georges, Lebel, Marc H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023310/
https://www.ncbi.nlm.nih.gov/pubmed/32530035
http://dx.doi.org/10.1093/jpids/piaa046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8023310/
https://www.ncbi.nlm.nih.gov/pubmed/32530035
http://dx.doi.org/10.1093/jpids/piaa046

Ejemplares similares